UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the Securities
Exchange
Act of 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
| ☐ |
Preliminary
Proxy Statement |
| ☐ |
CONFIDENTIAL,
FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) |
| ☐ |
Definitive
Proxy Statement |
| ☒ |
Definitive
Additional Materials |
| ☐ |
Soliciting
Material under § 240.14a-12 |
| CareCloud,
Inc. |
| (Name
of Registrant as Specified In Its Charter) |
| |
| |
| (Name
of Person(s) Filing Proxy Statement, if other than the Registrant) |
Payment
of Filing Fee (Check all boxes that apply):
| ☐ |
|
Fee
paid previously with preliminary materials. |
| |
|
|
| ☐ |
|
Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 9, 2024
CARECLOUD,
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36529 |
|
22-3832302 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
7
Clyde Road, Somerset, New Jersey, 08873
(Address
of principal executive offices, zip code)
(732)
873-5133
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
CCLD |
|
Nasdaq
Global Market |
| 11%
Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share |
|
CCLDP |
|
Nasdaq
Global Market |
| 8.75%
Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share |
|
CCLDO |
|
Nasdaq
Global Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
July 9, 2024, the Registrant issued a press release announcing the commencement of the solicitation of proxies to approve an amendment
to the Registrant’s Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Preferred Stock (“Series
A Certificate”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
On
July 9, 2024, the Registrant provided a slide presentation to accompany its proxy statement with respect to the solicitation of proxies
to approve an amendment to the Series A Certificate. A copy of the slides is attached hereto as Exhibit 99.2 and is incorporated herein
by reference.
The
information furnished pursuant to Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Safe
Harbor Statement
Statements
contained in the exhibits that state the Registrant’s or its management’s expectations or predictions of the future are forward-looking
statements intended to be covered by the safe harbor provisions of the Securities Act of 1933, as amended, and the Securities Exchange
Act of 1934, as amended. It is important to note that the Registrant’s actual results could differ materially from those projected
in such forward-looking statements. The Registrant does not assume any obligations to update any of the forward-looking statements contained
in the exhibits to reflect events that occur or circumstances that exist after the date on which they were made.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
|
CareCloud,
Inc. |
| |
|
|
| Date: |
July
9, 2024 |
By: |
/s/
A. Hadi Chaudhry |
| |
|
|
A.
Hadi Chaudhry |
| |
|
|
Chief
Executive Officer |
Exhibit
99.1
CareCloud
Proposes Amendment to the Terms of its Series A Preferred Stock
SOMERSET,
N.J., July 9, 2024 (GLOBE NEWSWIRE) — CareCloud, Inc. (the “Company”) (Nasdaq: CCLD CCLDO, CCLDP), a leader
in healthcare technology solutions for medical practices and health systems nationwide, today announced that it has begun soliciting
proxies from the holders (the “Series A Preferred Shareholders”) of its 11% Series A Cumulative Redeemable Perpetual Preferred
Stock (the “Series A Preferred Stock”) to approve an amendment to the Company’s Certificate of Designations, Preferences
and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Preferred Stock Proposal”). Under the Preferred
Stock Proposal, holders of Series A Preferred Stock would receive similar change of control protections to those afforded to holders
of the Company’s 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”).
The future dividends of the Series A Preferred Stock would mirror that of the Series B Preferred Stock, and the Company
would, going forward, have the right to exchange the shares of Series A Preferred Stock for shares of common stock at the liquidation
preference value of $25 per share, plus any accrued and unpaid dividends.
Mahmud
Haq, Founder and Executive Chairman of the Board of Directors of CareCloud, stated, “We are confident that the changes we
have proposed to the terms of our Series A Preferred Stock are in the best interest of our company and all classes of shareholders. These
changes would best position our shareholders for a future transaction, if any, and enable us to continue to add value as we grow CareCloud.”
The
Proxy. On July 8, 2024, the Company filed a Definitive Proxy Statement (the “Proxy”) relative to a Special Meeting of
Series A Preferred Shareholders (the “Special Meeting”). This Proxy, in turn, is the result of the capital structure analysis
that was performed by Citizens JMP, which was prompted by the Board’s exercise of its fiduciary duty in response to an unsolicited
indication of interest to acquire the Company (as more fully discussed in our press releases dated May 9 and May 13, 2024).
The
Proxy seeks approval of the Preferred Stock Proposal which, if approved by holders of two-thirds (66 2/3%) of the Series A Preferred
Stock, would modify the terms of the Series A Preferred Stock by:
| (i) | Change
of Control Rights. Adding a change of control provision, as presently afforded to holders
of Series B Preferred Stock, that would require an acquirer of a controlling interest
in the Company’s common stock to redeem (if requested) the Series A Preferred
Stock in exchange for shares of the Company’s common stock based on a $25 per
share liquidation preference plus any accumulated and unpaid dividends (as opposed
to the current terms which would permit an acquirer of the Company to leave the Series A
Preferred Stock outstanding after a transaction as a security of a public reporting
entity after paying any accumulated and unpaid dividends); |
| (ii) | Equivalent
Dividend Rate. Changing the dividend to 8.75% per annum (consistent with the dividend
of the Series B Preferred Stock); and |
| (iii) | Exchangeability.
Introducing an exchange feature that would enable the Company, at its option, to cause
the outstanding shares of the Series A Preferred Stock, at any time, to be automatically
exchanged for a number of shares of common stock equal to the quotient obtained by dividing
(1) the sum of (a) the $25.00 per share liquidation preference, and (b) the amount of any
accumulated and unpaid dividends on such share of Series A Preferred Stock being exchanged
by (2) the volume weighted average price of the shares of the Company’s common stock. |
Ownership
Interest of Directors and Named Officers. Directors and named executive officers of the Company beneficially owned the following
percentages of the below listed classes of shares as of June 30, 2023 and 2024, respectively, and during this period, the ownership
interests increased by the following percentages year-over-year:
| Class |
|
6/30/2023 |
|
|
6/30/2024 |
|
|
YoY
% increase |
|
| Common Stock |
|
|
34.7 |
% |
|
|
38.3 |
% |
|
|
10 |
% |
| Series A Preferred Stock |
|
|
0 |
% |
|
|
0 |
% |
|
|
0 |
% |
| Series B Preferred Stock |
|
|
1.8 |
% |
|
|
2.7 |
% |
|
|
50 |
% |
Date
and Timing. The Special Meeting date is August 23, 2024. This is consistent with the minimum timeline required by the Securities
and Exchange Commission, while affording approximately 40 days for the solicitation of proxies.
About
CareCloud
CareCloud
brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial
and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud
to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services
including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience
management (PXM) and digital health at www.carecloud.com.
Follow
CareCloud on LinkedIn, Twitter and Facebook.
Important
Additional Information and Where To Find It. CareCloud filed with the SEC a Definitive Proxy Statement on Schedule 14A on
July 8, 2024, with respect to its future solicitation of proxies for the Special Meeting of Series A Preferred Shareholders
(including any and all adjournments, postponements, continuations, and reschedulings thereof, the “Special Meeting”).
The information contained in this press release is merely a summary of certain relevant portions of the Definitive Proxy Statement
and it is important that Series A Preferred Shareholders review the entirety of the filing. SERIES A PREFERRED SHAREHOLDERS
ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER AMENDMENTS OR SUPPLEMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR
ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT CARECLOUD’S FILING. Investors and security holders
may obtain copies of these documents and other documents filed with the SEC by CareCloud free of charge through the website maintained
by the SEC at www.sec.gov. The Notice of the Special Meeting of Series A Preferred Shareholders and our Definitive Proxy
Statement for the Special Meeting, the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our Quarterly Report
on Form 10-Q for the quarterly period ended March 31, 2024 are available at www.sec.gov.
Forward-Looking
Statements
This
press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial
performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,”
“will,” “shall,” “should,” “could”, “intends,” “expects,” “plans,”
“goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,”
“predicts,” “possible,” “potential,” “target,” or “continue” or the negative
of these terms or other comparable terminology.
Our
operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could
materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking
statements in this press release include, without limitation, statements reflecting management’s expectations for future financial
performance and operating expenditures, expected growth, profitability and business outlook, the impact of pandemics on our financial
performance and business activities, and the expected results from the integration of our acquisitions.
These
forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are
uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s)
actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance
expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible
for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation,
risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and
existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and
properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop
new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies’
products and services competitive with ours, and other important risks and uncertainties referenced and discussed under the heading
titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission.
The
statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on
its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events
that occur or circumstances that exist after the date on which they were made.
SOURCE
CareCloud
Company
Contact:
Norman
Roth
Interim
Chief Financial Officer and Corporate Controller
CareCloud,
Inc.
nroth@carecloud.com
Investor
Contact:
Bill Korn
CareCloud,
Inc.
ir@carecloud.com
Exhibit 99.2
CareCloud (NASDAQ:CCLDP)
Historical Stock Chart
From Oct 2024 to Nov 2024
CareCloud (NASDAQ:CCLDP)
Historical Stock Chart
From Nov 2023 to Nov 2024
